Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

OP-EHEA191011_online 2313..2340 Page 1 Low-density lipoproteins cause atherosclerotic
cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus …

Background Lipoprotein (a) is a presumed risk factor for atherosclerotic cardiovascular
disease. Olpasiran is a small interfering RNA that reduces lipoprotein (a) synthesis in the …

Recent advances in human genetics, together with a large body of epidemiologic,
preclinical, and clinical trial results, provide strong support for a causal association between …

Compelling evidence supports a causal role for lipoprotein (a)(Lp (a)) in cardiovascular
disease. No pharmacotherapies directly targeting Lp (a) are currently available for clinical …

version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …

Importance Lipoprotein (a)(Lp [a]) is a low-density lipoprotein (LDL) cholesterol–like particle
bound to apolipoprotein (a). This novel marker of cardiovascular disease acts through …

Background Familial hypercholesterolemia is characterized by an elevated level of low-
density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic …

Background: Lipoprotein (a)[Lp (a)] may play a causal role in atherosclerosis. PCSK9
(proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce …

Background Lipoprotein (a) concentration is associated with cardiovascular events.
Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein (a) …